A Phase II Evaluation of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Overview
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.
Basic Trial Information
| Phase | Type | Status | Age | Protocol ID(s) |
|---|---|---|---|---|
| II | Treatment | Active On-going | 18+ | PIM 4972g |
|
Cancer Types Endometrial Cancer |
||||
Medical Professionals
http://www.clinicaltrials.gov/ct2/show/NCT01455493?term=PIM+4972G&rank=1
Explanation of Eligibility Criteria
- Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments
- Patients must have had no more than two prior chemotherapeutic regimens for endometrial carcinoma
- Disease that is measurable per RECIST v1.1
- No active infection requiring antibiotics
- Any hormonal therapy directed at the malignant tumor must be discontinued at least 2 weeks prior to first study treatment
- Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatment
- Adequate hematologic and end organ function
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please call our Clinical Research Center at 407.303.2059 for additional information.
Our Web site gives a description of the clinical trials offered at the FHCI. Read over the information carefully and fully consider all of your options. Because trials can frequently change, call our Clinical Research Center at 407.303.2059 for the most up-to-date information. Please reference the protocol number (listed on the top of this page under Study Summary) when inquiring about a clinical trial.
